Impact of end-product inhibition on the determination of in vitro metabolic clearance

References

• Ashforth EIL, Carlile DJ, Chenery R, Houston JB. 1995. Prediction of in vivo disposition from in vitro systems: Clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data. Journal of Pharmacology and Experimental Therapeutics 274:761–766.
   PubMed Web of Science ®Google Scholar
• Ashley JJ, Levy G. 1972. Inhibition of diphenylhydantoin elimination by its major metabolite. Research Communications in Chemical Pathology and Pharmacology 4:297–306.
   PubMedGoogle Scholar
• Carlile DJ, Stevens AJ, Ashforth EIL, Waghela D, Houston JB. 1998. In vivo clearance of ethoxycoumarin and its prediction from in vitro systems. Drug Metabolism and Disposition 26:216–221.
   PubMed Web of Science ®Google Scholar
• Carlile DJ, Zomorodi K, Houston JB. 1997. Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes and the intact liver: Studies with induced livers involving diazepam. Drug Metabolism and Disposition 25:903–911.
   PubMed Web of Science ®Google Scholar
• Chenery RJ, Ayrton A, Oldham HG, Standring P, Norman SJ, Seddon T, Kirby R. 1987. Diazepam metabolism in cultured hepatocytes from rat, rabbit, dog, guinea pig and man. Drug Metabolism and Disposition 15:312–317.
   PubMed Web of Science ®Google Scholar
• Fisher MB, Campanale K, Ackermann BL, Vandenbranden M, Wrighton SA. 2000. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metabolism and Disposition 28:560–566.
   PubMed Web of Science ®Google Scholar
• Fisher MB, Paine MF, Strelevitz TJ, Wrighton SA. 2001. The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metabolism Reviews 33:273–297.
   PubMed Web of Science ®Google Scholar
• Foti RS, Fisher MB. 2004. Impact of incubation conditions on bufuralol human clearance predictions: Enzyme lability and non-specific binding. Drug Metabolism and Disposition 32:295–304.
   PubMed Web of Science ®Google Scholar
• Houston JB. 1994. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochemical Pharmacology 47:1469–1479.
   PubMedGoogle Scholar
• Houston JB, Carlile DJ. 1997. Prediction of hepatic clearance from microsomes, hepatocytes and liver slices. Drug Metabolism Reviews 29:891–922.
   PubMed Web of Science ®Google Scholar
• Houston JB, Kenworthy KE, Galetin A. 2003. Typical and atypical enzyme kinetics. In: Lee JS, Obach RS, Fisher MB, editors. Drug metabolizing enzymes. Cytochrome P450 and other enzymes in drug discovery and development. Lausanne: Fontis Media, and New York: Marcel Dekker. pp 211–254.
   Google Scholar
• Ito K, Houston JB. 2004. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharmaceutical Research 21:785–792.
   PubMed Web of Science ®Google Scholar
• Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, Sugiyama Y. 1997. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacology and Therapeutics 73:147–171.
   PubMed Web of Science ®Google Scholar
• Jones HM, Hallifax D, Houston JB. 2004. Quantitative prediction of the in vivo inhibition of diazepam metabolism by omeprazole using rat liver microsomes and hepatocytes. Drug Metabolism and Disposition 32:572–580.
   PubMed Web of Science ®Google Scholar
• Jones HM, Houston JB. 2004. Use of the substrate depletion approach for determining in vitro metabolic clearance: Time dependencies in hepatocyte and microsomal incubations. Drug Metabolism and Disposition 32:973–982.
   PubMed Web of Science ®Google Scholar
• Kitagawa H, Esumi Y, Kurosawa S, Sekine S, Yokoshima T. 1979. Metabolism of 8-chloro-6-(o-chloropheny1)-1-methyl-4H-s-triazolo[4,3-a] [1,4]benzodiazepine, triazolarn, a new central depressant. II. Identification and determination of metabolites in rats and dogs. Xenobiotica 9:429–439.
   Google Scholar
• Lave T, Dupin S, Schmitt C, Valles B, Ubead G, Chou RC, Jaeck D, Coassolo P. 1997. The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharmaceutical Research 14:152–155.
   PubMed Web of Science ®Google Scholar
• Levy G, Ashley JJ. 1972. Effect of an inhibitor of glucuronide formation on elimination kinetics of diphenylhydantoin in rats. Journal of Pharmaceutical Sciences 62:161–162.
   Web of Science ®Google Scholar
• Little JM, Lehman PA, Nowell S, Samokyszyn V, Radominska A. 1997. Glucuronidation of all-trans-rannoic acid and 5,6-epoxy-all-trans-rannoic acid. Drug Metabolism and Disposition 25:5–11.
   PubMed Web of Science ®Google Scholar
• Madan A, Usuki E, Burton LA, Ogilvie BW, Parkinson A. 2002. In vitro approaches for studying the inhibition of drug-metabolising enzymes and identifying the drug-metabolising enzymes responsible for the metabolism of drugs. In: Rodrigues A, editor. Drug-drug interactions. New York: Marcel-Dekker. pp 217–293.
   Google Scholar
• Margolis JM, Obach RS. 2003. Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: Implications for relating in vitro inhibition data to in vivo drug interactions. Drug Metabolism and Disposition 31:606–611.
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Riley RJ. 2001. Predicting drug pharmacokinetics in humans from in vitro metabolism studies. Biochemical Society Transactions 29:135–139.
   PubMed Web of Science ®Google Scholar
• Obach RS. 1999. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metabolism and Disposition 27:1350–1359.
   PubMed Web of Science ®Google Scholar
• Obach RS. 2001. The prediction of human clearance from hepatic microsomal data. Current Opinions in Drug Discovery and Development 4:36–44.
   PubMedGoogle Scholar
• Obach RS, Reed-Hagen AE. 2002. Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using the substrate depletion approach. Drug Metabolism and Disposition 30:831–837.
   PubMed Web of Science ®Google Scholar
• Savenije-Chapel EM, Bast A, Noordhoek J. 1985. Inhibition of diazepam metabolism in microsomal and perfumed liver preparations of the rat by desmethyldiazepam, N-methyloxazepam and oxazepam. European Journal of Drug Metabolism and Pharmacokinetics 10:15–20.
   PubMedGoogle Scholar
• Seddon T, Michelle I, Chenery RJ. 1989. Comparative drug metabolism of diazepam in hepatocytes isolated from man, rat, monkey and dog. Biochemical Pharmacology 38:1657–1665.
   PubMed Web of Science ®Google Scholar
• Shou M, Mei Q, Ettore MW, Dai R, Baille TA, Rushmore TH. 1999. Sigmoidal kinetic model for two co-operative substrate binding sites in a cytochrome P450 3A4 active site: An example of the metabolism of diazepam and its derivatives. Biochemical Journal 340:845–853.
   PubMed Web of Science ®Google Scholar
• Tran TH, Von Moltke LL, Venkatakrishnan K, Granda BW, Gibbs MA, Obach RS, Harmatz JS, Greenblatt DJ. 2002. Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. Drug Metabolism and Disposition 30:1441–1445.
   PubMed Web of Science ®Google Scholar
• Zomorodi K, Carlile DJ, Houston JB. 1995. Kinetics of diazepam metabolism in rat hepatic microsomes and hepatocytes and their use in predicting in vivo hepatic clearance. Xenobiotica 25:907–916.
   PubMed Web of Science ®Google Scholar